Body Mass Index and Sudden Cardiac Death in Japanese Patients After Acute Myocardial Infarction: Data From the JCAD Study and HIJAMI-II Registry

Tsuyoshi Shiga, MD; Takahide Kohro, MD; Hiro Yamasaki, MD; Kazutaka Aonuma, MD; Atsushi Suzuki, MD; Hiroshi Ogawa, MD; Nobuhisa Hagiwara, MD; Tsutomu Yamazaki, MD; Ryozo Nagai, MD; Hiroshi Kasanuki, MD

Background—Although an “obesity paradox” exists in patients after myocardial infarction, the association between obesity and the risk of sudden cardiac death (SCD) is limited. The aim of this study was to determine whether obesity is associated with an increased risk of SCD in Japanese survivors of acute myocardial infarction.

Methods and Results—Pooled data from 2 cohort studies in Japan, JCAD (Japanese Coronary Artery Disease) study and the Heart Institute of Japan Acute Myocardial Infarction-II (HIJAMI-II) registry, comprising of 6216 patients (mean age 65±11 years, 75.2% male) with acute myocardial infarction who were discharged alive, were studied. The patients were categorized into the following body mass index (BMI) groups at baseline according to the World Health Organization classification for Asian populations: BMI <18.5 kg/m² (n=335), 18.5 to 23 kg/m² (n=2371), 23 to 27.5 kg/m² (n=2823), and ≥27.5 kg/m² (n=687). The main outcomes were all-cause mortality and SCD. During an average follow-up period of 3.6±1.4 years, all-cause mortality was 10.1%, and SCD was 1.2%. Patients with BMI <18.5 kg/m² had the highest rate of all-cause mortality (adjusted hazard ratio, 1.61; 95% confidence interval, 1.20–2.16), but high BMI (≥27.5 kg/m²) was not associated with mortality compared with patients in the group with BMI ≥18.5 kg/m². However, the long-term risk of SCD was increased in the group with BMI ≥27.5 kg/m² (adjusted hazard ratio, 2.97; 95% confidence interval, 1.24–7.15). Multivariate analysis revealed that BMI ≥27.5 kg/m² was associated with an increased risk of SCD (hazard ratio, 2.78; 95% confidence interval, 1.35–5.74).

Conclusions—Obesity (BMI ≥27.5 kg/m²) was associated with the risk of SCD in Japanese patients after myocardial infarction, although an obesity paradox was found for all-cause mortality. (J Am Heart Assoc. 2018;7:e008633. DOI: 10.1161/JAHA.118.008633.)

Key Words: body mass index • left ventricular ejection fraction • myocardial infarction • obesity • sudden cardiac death

Obesity is an important predictor of myocardial infarction (MI) and mortality in the general population. However, several studies have revealed an obesity paradox in patients after MI: low body mass index (BMI) is associated with mortality in high-risk patients with MI in the primary percutaneous coronary intervention era. Sudden cardiac death (SCD) is one of the major causes of death in patients with coronary artery disease (CAD) and MI. Recent large population-based cohort studies have reported that higher BMI is associated with an increased risk of SCD, although these findings are controversial. Data on the association between obesity and the risk of SCD and ventricular tachyarrhythmias in patients with MI are limited. Moreover, whether obese patients who survive an acute MI have a long-term risk of SCD is unclear.

The World Health Organization (WHO) expert consultation recommended that the cutoff point for obesity be 27.5 kg/m² or higher for the Asian population because Asian individuals have different associations between BMI, body fat, and health risks than individuals in the United States and Europe.
BMI and SCD in Japanese MI Patients  
Shiga et al

Clinical Perspective

What Is New?

- Our study demonstrated a U-shaped relationship between body mass index and risk of sudden cardiac death in Japanese patients after acute myocardial infarction, although an “obesity paradox” existed for all-cause mortality.
- In addition, our study showed obese patients (body mass index $\geq 27.5$ kg/m$^2$) exhibited an increased long-term risk of sudden cardiac death.

What Are the Clinical Implications?

- Our findings suggest that a substantial reassessment is needed of the importance of obesity for sudden cardiac death prevention in patients after myocardial infarction and that obese patients with myocardial infarction should be encouraged to pursue weight-loss strategies.

Exposure Assessment

In these studies, the baseline demographic values, weights, and heights of all patients were recorded to calculate BMI as weight in kilograms divided by height in meters squared (kg/m$^2$). Patients were divided into 4 prespecified BMI groups using the World Health Organization classification for Asian populations: BMI $<18.5$ kg/m$^2$ denoted underweight, 18.5 to 23 kg/m$^2$ denoted an increasing but acceptable risk, 23 to 27.5 kg/m$^2$ denoted an increased risk, and $\geq 27.5$ kg/m$^2$ denoted a high risk.

LVEF was obtained from the baseline database of both studies containing the results of ventriculography, echocardiography, or radionuclide ventriculography, performed before hospital discharge.

Outcome Assessment

The prespecified outcomes in this study were all-cause mortality and SCD. To standardize the definition of SCD in this analysis of the combined studies, all fatal cases were reviewed and adjudicated by a committee of investigators (H.Y., T.K., T.S., and K.A.). Definite SCD was defined as sudden, unexpected death attributable to a cardiac cause such as a sudden cardiac arrest in a previously stable individual. Possible SCD was defined as unexpected, endogenous death within 24 hours after last having been seen alive that was not related to a specific cause of circulatory failure or a cause other than the heart. In this study, definite SCD and possible out-of-hospital SCD were included as SCD.
BMI and SCD in Japanese MI Patients  Shiga et al

Determination of LVEF

LVEF was calculated from the results of ventriculography, echocardiography, or radionuclide ventriculography performed during hospitalization due to acute MI. All LVEF determinations were performed by independent investigators (T.K. and A.S.) who were blinded to the patients’ data.

Statistical Analysis

Data are presented as the mean±standard deviation and median with the interquartile range or frequency. One-way ANOVA was used to compare groups with respect to normally distributed continuous variables, and the Kruskal-Wallis test was used for other variables. Categorical variables were subjected to chi-squared analysis. Cumulative probabilities of all-cause mortality and SCD were estimated with the Kaplan-Meier method from enrollment data and by means of a comparison of cumulative events based on BMI with the log-rank test. To evaluate the influence of BMI on subsequent death events, unadjusted and adjusted Cox proportional hazards models were evaluated according to BMI group: BMI <18.5, 18.5 to 23, 23 to 27.5, and ≥27.5 kg/m². The Cox model was adjusted for age, sex, risk factors, LVEF, and medications. The proportionality assumption was checked by inspection of the log-log plots. Univariate and multivariate analyses using the Cox model were performed to determine the relationships between the BMI group and SCD, independent of the following confounders: age, sex, each coronary risk factor, LVEF, coronary revascularization, and each medication. A forward stepwise method was used for the multivariate analyses, with entry or removal based on a P<0.10.

Two-tailed P<0.05 were considered to indicate a statistically significant difference. Data analyses were performed using SPSS statistical software (version 11.01, SPSS Inc, Chicago, IL, USA).

Results

Of 6216 MI survivors, 86.4% received coronary revascularization during their hospitalization. During an average follow-up of 3.6±1.4 years, the rate of all-cause mortality was 10.1% and the rate of SCD was 1.2%. In this study, the mean BMI was 23.6±3.3 kg/m², and the median BMI was 23.4 kg/m² (interquartile range, 21.5–25.6) (Figure 1). The patient distribution according to BMI was as follows: 5.4% had a BMI of <18.5 kg/m², 38.1% had a BMI of 18.5 to 23 kg/m², 45.4% had a BMI of 23 to 27.5 kg/m², and 11.1% had a BMI of ≥27.5 kg/m².

The patients’ baseline characteristics are shown in Table 1. Patients with a BMI of ≥27.5 kg/m² were younger and had higher LVEF and systolic and diastolic blood pressure values.

The incidences of complicated coronary risk factors such as hypertension, dyslipidemia, diabetes mellitus, smoking, and a family history of CAD were higher in this group of patients.

With regard to medications at discharge, use of aspirin, angiotensin-converting enzyme inhibitors/angiotensin II receptor blockers, β-blockers, statins, and calcium channel blockers were more frequent in this group.

Kaplan-Meier curves for all-cause mortality in the 4 groups are shown in Figure 2. There was a significantly lower incidence of all-cause mortality in patients with a BMI of 23.5 to 27.5 kg/m² and ≥27.5 kg/m² compared with the others (P<0.001). Kaplan-Meier curves for SCD-free status in the 4 groups are shown in Figure 3. There was a significantly higher incidence of SCD in patients with a combined BMI <18.5 and ≥27.5 kg/m² compared with the others (P=0.005).

The unadjusted Cox proportional hazards model demonstrated an increased risk of 3-year all-cause death in the lowest BMI group (BMI <18.5 kg/m²) and a U-shaped relationship between BMI and the risk of 3-year SCD, with an increased risk in both patients with a BMI of <18.5 kg/m² and those with a BMI of ≥27.5 kg/m² (Table 2). After adjusting for age, sex, risk factors, LVEF, and medications, the risk of SCD was significantly higher in patients with a BMI of ≥27.5 kg/m² (adjusted hazard ratio, 2.97, 95% confidence interval, 1.24–7.15) compared with those with a BMI of 18.5 to 23 kg/m² (Table 2).

Multivariate analysis revealed that a BMI of ≥27.5 kg/m² was associated with an increased risk of SCD (hazard ratio 2.78, 95% confidence interval, 1.35–5.74; P=0.006), which was independent of LVEF ≤30% and multivessel disease (Table 3).

Discussion

Our study revealed an obesity paradox in Japanese patients who survived an acute MI, whereby low BMI (<18.5 kg/m²)
was associated with the highest rate of all-cause mortality and high BMI (≥27.5 kg/m²) was not associated with mortality. A U-shaped relationship between BMI and the risk of SCD exists in Japanese patients after acute MI. After a multivariable adjustment, patients with high BMI (≥27.5 kg/m²) had an increased risk of SCD compared with those with a BMI of 18.5 to 23 kg/m². Furthermore, our results suggested that high BMI is a risk factor of SCD independent of LVEF.

Obesity is a metabolic disorder and an important and well-established risk factor for cardiovascular disease, including

### Table 1. Baseline Patient Characteristics by BMI Category

|                  | BMI <18.5 (n=335) | BMI 18.5 to 22.9 (n=2371) | BMI 23.0 to 27.4 (n=2823) | BMI ≥27.5 (n=687) | P Value |
|------------------|-------------------|---------------------------|---------------------------|-------------------|---------|
| BMI, kg/m²       | 17.3±1.1          | 21.2±1.2                  | 24.8±1.2                  | 29.6±2.3          | <0.0001 |
| Age, y           | 73±11             | 68±11                     | 64±11                     | 59±12             | <0.0001 |
| Male             | 182 (54)          | 1724 (73)                 | 2239 (79)                 | 530 (77)          | <0.0001 |
| Smoker           | 160 (48)          | 1276 (54)                 | 1673 (59)                 | 411 (60)          | <0.0001 |
| Hypertension     | 165 (49)          | 1178 (50)                 | 1629 (58)                 | 465 (68)          | <0.0001 |
| Diabetes mellitus| 98 (29)           | 781 (33)                  | 1042 (37)                 | 310 (45)          | <0.0001 |
| Dyslipidemia     | 81 (24)           | 900 (38)                  | 1351 (48)                 | 418 (61)          | <0.0001 |
| Family history of CAD | 42 (13) | 337 (14)                  | 480 (17)                  | 134 (20)          | 0.0007  |
| Systolic BP, mm Hg | 128±25          | 129±24                    | 131±25                    | 136±24            | <0.0001 |
| Diastolic BP, mm Hg | 72±14           | 74±15                     | 76±15                     | 80±15             | <0.0001 |
| LVEF, %          | 51±14             | 52±13                     | 53±13                     | 53±12             | 0.0168  |
| Multivessel disease | 153 (46)       | 1103 (47)                 | 1273 (45)                 | 297 (43)          | 0.5059  |
| Left main lesion | 7 (2)             | 54 (2)                    | 51 (2)                    | 6 (1)             | 0.1123  |
| Coronary revascularization | 264 (79) | 2031 (86)                 | 2483 (89)                 | 597 (87)          | <0.0001 |

Values are mean±SD or n (%). ACE indicates angiotensin-converting enzyme; ARB, angiotensin II receptor blocker; BMI, body mass index; BP, blood pressure; CAD, coronary artery disease; LVEF, left ventricular ejection fraction.

**Figure 2.** Kaplan-Meier curve for all-cause death in patients with myocardial infarction by body mass index (BMI) groups.

**Figure 3.** Kaplan-Meier curve for sudden cardiac death in patients with myocardial infarction by body mass index (BMI) groups.

DOI: 10.1161/JAHA.118.008633

Journal of the American Heart Association
Table 2. Unadjusted and Adjusted 3-Year All-Cause Mortality and Sudden Cardiac Death

| BMI category          | All-cause mortality (%) | Sudden cardiac death (%) | Hazard ratio (95% CI) | Hazard ratio (95% CI) |
|-----------------------|-------------------------|--------------------------|-----------------------|-----------------------|
| BMI <18.5 (n=335)     | 69 (20.6)               | 6 (1.8)                  | 2.60 (1.98–3.42)      | 2.45 (0.88–6.81)      |
| BMI 18.5 to 22.9 (n=2371) | 202 (8.5)             | 17 (0.7)                 | 1 (reference)         | 1 (reference)         |
| BMI 23.0 to 27.4 (n=2823) | 149 (5.3)             | 22 (0.8)                 | 0.61 (0.49–0.75)      | 0.92 (0.45–1.85)      |
| BMI ≥27.5 (n=687)     | 30 (4.4)                | 11 (1.6)                 | 0.50 (0.34–0.73)      | 2.17 (1.02–4.63)      |

Table 3. Multivariate Risk Ratios for 3-Year Sudden Cardiac Death

| Risk factor                        | Risk Ratio (95% CI) | P Value |
|------------------------------------|---------------------|---------|
| Age (1-year increase)              | 1.02 (0.99–1.05)    | 0.106   |
| Family history of CAD              | 0.33 (0.10–1.08)    | 0.067   |
| LVEF ≤30%                          | 2.51 (1.06–5.96)    | 0.038   |
| Multivessel disease                | 4.27 (2.11–8.64)    | <0.001  |
| BMI <18.5                          | 1.65 (0.57–4.76)    | 0.353   |
| BMI ≥27.5                          | 2.78 (1.35–5.74)    | 0.006   |

CAD, in the general population; obesity is also associated with increased cardiovascular and with all-cause morbidity and mortality. Obese patients with acute MI are younger and have a higher incidence of risk factors and higher LVEF compared with nonobese patients. For the primary prevention of CAD, obesity is recognized as a potent risk factor and an opportunity for therapeutic intervention to prevent cardiovascular disease. However, recent reports have shown that obesity (high BMI) itself does not present a mortality risk but is associated with a better prognosis (obesity paradox) in CAD patients receiving secondary care; these patients received appropriate therapy, including percutaneous coronary intervention and guideline-based medications, such as aspirin, β-blockers, and statins. Our study also observed the obesity paradox, and patients with a BMI of ≥27.5 kg/m² also received several cardiovascular drugs.

Das et al reported that extreme obesity is independently associated with higher in-hospital mortality in patients with ST-segment elevation MI as found through the analysis of a large registry. Romero-Corral et al performed a meta-analysis of 40 cohort studies of patients with CAD and reported that a U-shaped interaction existed between BMI and cardiovascular mortality but not total mortality and that mortality increased in patients who were extremely obese (BMI ≥35 kg/m²). These results indicate that obesity remains a risk factor for cardiovascular mortality, including SCD, in patients with CAD despite their younger ages, better LV function, and receipt of optimal therapy.

The reason obese patients have a risk of SCD after MI despite these advantages is not well understood. Recently, Eranti et al reported that overweight and obese patients were at increased risk for SCD in a general population of 10 543 middle-aged subjects. Obesity itself may contribute to the development of arrhythmogenic substrates in the ventricle. Obesity is reported to be independently associated with LV hypertrophy, which leads to cardiac structural and functional remodeling. An autopsy study of 28 obese patients (22 SCDs) revealed LV dilatation, severe coronary atherosclerosis, and concentric LV hypertrophy and histologically confirmed cardiomyocyte hypertrophy in these patients. Some reports have shown QT prolongation or an increased late potential in obese patients, which may provoke arrhythmia.

Reduced LVEF is the best available predictor of SCD in survivors of MI. In this study, a high BMI was a risk factor of SCD independent of LVEF. A subanalysis of the MADIT-II (Multicenter Automatic Defibrillator Implantation Trial II) included high-risk patients with a previous MI and LVEF ≤30% and reported that an independent inverse association existed between the BMI values and risk of all-cause mortality and SCD. In the MADIT-II, patients were randomized to receive a prophylactic implantable cardioverter-defibrillator or conventional medical therapy at a 3:2 ratio. In patients with an implantable cardioverter-defibrillator, however, obesity (BMI ≥30 kg/m²) was a significant risk factor for ventricular tachyarrhythmias requiring appropriate implantable...
cardioverter-defibrillator therapy. From these results, obesity might contribute to the development of tachyarrhythmia, which can lead to SCD, in high-risk patients after MI. Multivessel disease was found to be an independent risk factor for SCD in this study. Multivessel disease is a well-known risk factor of mortality in patients with MI. A small study showed that multivessel disease was not a predictor of long-term SCD in MI patients who received reperfusion therapy, but there are few data on whether multivessel disease is a risk factor for SCD.

In this study, only 1.2% of patients experienced SCD after acute MI. Primary percutaneous coronary intervention in acute MI is central to optimal ST-elevation MI treatment and reduces infarct size, minimizes myocardial damage, preserves LV function, and decreases morbidity and mortality. Early revascularization contributes to an improvement in LV function after acute MI, and this improvement will lead to better survival, including decreasing SCD. In our study, 86.4% of patients received early coronary revascularization during hospitalization due to acute MI. Currently, most patients with acute MI received early coronary revascularization, such as primary percutaneous coronary intervention, and a low incidence of SCD has been reported in patients with acute MI who receive primary percutaneous coronary intervention in the United States and Europe as well as in Japan.

Our findings indicated that obese patients who survive an acute MI have a long-term risk of SCD. Although lifestyle modifications and medical therapies or implantable cardioverter-defibrillators may inhibit SCD, we could not determine whether intentional weight loss was effective in the prevention of SCD or in the reduction of risk in obese patients with MI. To make these determinations, further investigations are needed.

Study Limitations

This study had some limitations. First, the present study used data from 2 past registries and thus could not account for confounders, such as frailty, cognitive impairment, chronic obstructive pulmonary disease, and peripheral artery disease, that were not contained in either database. In addition, the small number of subjects. However, the 2 confirmatory methods, Kaplan-Meier analysis and multivariate adjustment, that were employed in the present study consistently indicated an association between high BMI and risk of SCD in patients after MI in both cohorts. Second, longitudinal measurements of body weight and LVEF were not performed to evaluate the improvement in LV function after MI. Third, treatment bias existed because this was an observational study. β-Blocker use was limited in this study.

The original data were obtained between 1999 and 2002. Fourth, information about culprit and other vessels on coronary angiography was not fully available, so we could not assess the possible role of an organic coronary stenosis lesion in LVEF or subsequent death.

Conclusions

Our study demonstrated a U-shaped relationship between BMI and risk of SCD in Japanese patients after acute MI, although an obesity paradox existed for all-cause mortality. Obese patients (BMI ≥ 27.5 kg/m²) exhibited an increased long-term risk of SCD. Our findings suggest that a substantial reassessment is needed of the importance of obesity for SCD prevention in patients after MI and that obese patients with MI should be encouraged to pursue weight-loss strategies.

Acknowledgments

The authors thank the secretarial staff and investigators of the participating hospitals for contributing to this study and also thank Dr. Satoru Shimizu for his helpful comments.

Sources of Funding

The JCAD study was supported by the Japan Heart Foundation, and the HIJMAI-II was supported by funds from the Japan Research Promotion Society for Cardiovascular Diseases.

Disclosures

None.

References

1. Hubert HB, Feinleib M, McNamara PM, Castelli WP. Obesity as an independent risk factor for cardiovascular disease: a 26-year follow-up of participants in the Framingham Heart Study. Circulation. 1983;67:968–977.
2. Yusuf S, Hawken S, Ounpuu S, Bautista L, Franzosi MG, Commerford P, Lang CC, Rumboldt Z, Onen CL, Lisheng L, Tanomsup S, Wangai P Jr, Razak F, Sharma AM, Anand SS; INTERHEART Study Investigators. Obesity and the risk of myocardial infarction in 27,000 participants from 52 countries: a case-control study. Lancet. 2005;366:1640–1649.
3. Nikolsky E, Stone GW, Grines CL, Cox DA, Garcia E, Tcheng JE, Griffin JJ, Guagliumi G, Stuckey T, Turco M, Negoita M, Lansky AJ, Mehran R. Impact of body mass index on outcomes after primary angioplasty in acute myocardial infarction. Am Heart J. 2006;151:168–175.
4. Romero-Corral A, Montori VM, Somers VK, Korinek J, Thomas RJ, Allison TG, Moockadam F, Lopez-Jimenez F. Association of bodyweight with total mortality and with cardiovascular events in coronary artery disease: a systematic review of cohort studies. Lancet. 2006;368:666–678.
5. Bucholz EM, Rathore SS, Reid KJ, Jones PG, Chan PS, Rich MW, Spertus JA, Krumholz HM. Body mass index and mortality in acute myocardial infarction patients. Am J Med. 2012;125:796–803.
6. Myerburg RJ, Junttila MJ. Sudden cardiac death caused by coronary heart disease. Circulation. 2012;125:1043–1052.
7. Adabag S, Huxley RR, Lopez FL, Chen LY, Sotoodehnia N, Siscovick D, Deo R, Konety S, Alonso A, Folsom AR. Obesity related risk of sudden cardiac death in the Atherosclerosis Risk in Communities study. Heart. 2015;101:215–221.
8. Chiue SE, Sun Q, Sandhu RK, Tedrow U, Cook NR, Manson JE, Albert CM. Adiposity throughout adulthood and risk of sudden cardiac death in women. *JACC Clin Electrophysiol*. 2015;1:520–528.

9. Choy B, Hansen E, Moss AJ, McNitt S, Zareba W, Goldberg I; Multicenter Automatic Defibrillator Implantation Trial-II Investigators. Relation of body mass index to sudden cardiac death and the benefit of implantable cardioverter-defibrillator in patients with left ventricular dysfunction after healing of myocardial infarction. *Am J Cardiol*. 2010;105:581–586.

10. Singh JP, Hall WJ, McNitt S, Wang H, Daubert JP, Zareba W, Ruskin JN, Moss AJ; MADIT-II Investigators. Factors influencing appropriate firing of the implanted defibrillator for ventricular tachycardia/fibrillation: findings from the Multicenter Automatic Defibrillator Implantation Trial II (MADIT-II). *J Am Coll Cardiol*. 2005;46:1712–1720.

11. Pietrasik G, Goldberg I, McNitt S, Moss AJ, Zareba W. Obesity as a risk factor for sustained ventricular tachyarrhythmias in MADIT II patients. *J Cardiovasc Electrophysiol*. 2007;18:181–184.

12. WHO Expert Consultation. Appropriate body-mass index for Asian populations and its implications for policy and intervention strategies. *Lancet*. 2004;363:157–163.

13. Hozawa A, Okamura T, Oki I, Murakami Y, Kadowaki T, Nakamura K, Miyamatsu N, Hayakawa T, Kita Y, Nakamura Y, Nakamura Y, Abbott RD, Okayama A, Ueshima H; NIPPON DATA80 Study Group. Relationship between BMI and all-cause mortality in Japan: NIPPON DATA80. *Obesity (Silver Spring)*. 2008;16:1714–1717.

14. Zheng W, McLerran DF, Rolland B, Zhang X, Inoue M, Matsuo K, He J, Gupta VL, Habecker BA. Sympathetic cardiac hyperinnervation and atrial autonomic imbalance in diet-induced obesity promote cardiac arrhythmias. *Am J Physiol Heart Circ Physiol*. 2013;305:H1530–H1537.

15. Hozawa A, Okamura T, Oki I, Murakami Y, Kadowaki T, Nakamura K, Miyamatsu N, Hayakawa T, Kita Y, Nakamura Y, Nakamura Y, Abbott RD, Okayama A, Ueshima H; NIPPON DATA80 Study Group. Relationship between BMI and all-cause mortality in Japan: NIPPON DATA80. *Obesity (Silver Spring)*. 2008;16:1714–1717.

16. Zheng W, McLerran DF, Rolland B, Zhang X, Inoue M, Matsuo K, He J, Gupta VL, Habecker BA. Sympathetic cardiac hyperinnervation and atrial autonomic imbalance in diet-induced obesity promote cardiac arrhythmias. *Am J Physiol Heart Circ Physiol*. 2013;305:H1530–H1537.

17. Shiga T, Hagiwara N, Ogawa H, Takagi A, Nagashima M, Yamauchi T, Tsurumi Y, Koyanagi R, Kasanuki H; Heart Institute of Japan Acute Myocardial Infarction-II (HIJAMI-II) Investigators. Sudden cardiac death and left ventricular dysfunction in a de-presentation, treatment, and in-hospital outcomes of 50,149 patients with ST-elevation myocardial infarction from the NCDR (National Cardiovascular Data Registry). *J Am Coll Cardiol*. 2011;58:2642–2650.

18. Das SR, Alexander KP, Chen AY, Powell-Wiley TM, Diercks DB, Peterson ED, Roe MT, de Lemos JA. Impact of body weight and extreme obesity on the presentation, treatment, and in-hospital outcomes of 50,149 patients with ST-elevation myocardial infarction from the NCDR (National Cardiovascular Data Registry). *J Am Coll Cardiol*. 2011;58:2642–2650.

19. Eranti A, Aro AL, Kerola T, Tikkanen JT, Rissanen HA, Anttonen O, Junttila MJ, Knuuti J, Viskari E, Viikala T. Body mass index as a predictor of sudden cardiac death and usefulness of the electrocardiogram for risk stratification. *Am J Cardiol*. 2016;117:388–393.

20. Abele ED, Litwin SE, Sweeney G. Cardiac remodeling in obesity. *Physiol Rev*. 2008;88:389–419.

21. Duflou J, Virmanni R, Rabin I, Burke A, Farb A, Smialek J. Sudden death as a result of heart disease in morbid obesity. *Am Heart J*. 1995;130:306–313.

22. el-Gamal A, Gallagher D, Nawras A, Gandhi P, Gomez J, Allison DB, Steinberg JS, Shumacher D, Blank R, Heymsfield SB. Effects of obesity on QT, RR, and Q/Tc intervals. *Am J Cardiol*. 1995;75:956–959.

23. Huang H, Amin V, Gurin M, Gandhi P, Gomez J, Allison DB, Steinberg JS, Shumacher D, Blank R, Heymsfield SB. Diet-induced obesity causes long QT and reduces transcription of voltage-gated potassium channels. *J Mol Cell Cardiol*. 2013;59:151–158.

24. Lalani AP, Kann B, John J, Ferrick KJ, Huber MS, Shapiro LE. Abnormal signal-averaged electrocardiogram (SAECG) in obesity. *Obes Res*. 2000;8:220–228.

25. McCully BH, Hasan W, Streiff CT, Houle JC, Woodward WR, Giraud GD, Brooks VL, Habecker BA. Sympathetic cardiac hyperinnervation and atrial autonomic imbalance in diet-induced obesity promote cardiac arrhythmias. *Am J Physiol Heart Circ Physiol*. 2013;305:H1530–H1537.

26. McLaughlin MG, Zimetbaum P, Costantini C, Stone GW. Impact of multivessel disease on reperfusion success and clinical outcomes in patients undergoing primary percutaneous coronary intervention for acute myocardial infarction. *Eur Heart J*. 2009;30:2016–2025.

27. van der Schaaf RJ, Timmer JR, Ottervanger JP, Hoorn JC, de Boer MJ, Suryapranata H, Zijlstra F, Dambrik LH. Long-term impact of multivessel disease on cause-specific mortality after ST-elevation myocardial infarction treated with reperfusion therapy. *Heart*. 2006;92:1760–1763.

28. Ottervanger JP, Ramdat Misier AR, Dambrink JH, de Boer MJ, Hoorn JC, Gosselink AT, Suryapranata H, Reiffers S, van’t Hof AW; Zwolle Myocardial Infarction Study Group. Mortality in patients with left ventricular ejection fraction ≤30% after primary percutaneous coronary intervention for ST-elevation myocardial infarction. *Am J Cardiol*. 2007;100:793–797.

29. Sharma PP, Greenlee RT, Anderson KP, Chyou PH, Osorio HJ, Smith PN, Hayes JH, Vlaidil H. Prevalence and mortality of patients with myocardial infarction and reduced left ventricular ejection fraction in a defined community: relation to the second multicenter automatic defibrillator implantation trial. *J Interv Card Electrophysiol*. 2007;19:157–164.